Monthly Archives: November 2015

The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today.  There are now multiple stories of patients getting “cured” of rare diseases, responding

This blog was written by Kevin Pojasek, CEO at Quartet and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Therapeutic areas and modalities regularly fall in and out fashion usually when promising scientific approaches run aground in

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. For a great company, an IPO is a financing event. Not an exit. Not the end. This is important to